David Venables

David Venables serves as CEO at Skylark Therapeutics. Skylark Therapeutics operates in the research sector with approximately 40.0 employees. The company is headquartered in London, England. Skylark Therapeutics generates annual revenue of 1333000.0. To date, Skylark Therapeutics has raised 17600545.0 in total funding, with the most recent round being Other.

Industry & Role Insights

• • MessageCEO tracks 2,961 executives in the research sector.
• • 10,137 executive contacts are available in England.
• • Our database includes 201,468 c suite-level executives.

Outlook Amazon AWS Google Analytics Nginx

biotechnology research gene silencing programmable therapies advanced therapies crispr cellular reprogramming tumor microenvironment ipsc technology rna interference therapeutic development regenerative medicine oncology specific gene targeting micrornas gene editing multiplex silencing cell-based therapies hypoimmunogenicity autologous products allogeneic products disease targeting cell identity gene expression control safety & efficacy programmable platforms biotechnology pharmaceuticals partnerships investor relations innovation in cell therapy clinical applications car t cell immunotherapy regulatory profiles tunable expression stable silencing biomedical research scientific presentations therapeutics pipeline pre-clinical validation synergistic approaches predictable outcomes healthcare advancements therapeutic applications cell engineering scientific expertise funding opportunities collaborative research hospital & health care medical

SN

Srikanth Nandiraju Chief Technology Officer at 1Cell.Ai Inc.

SD

Surinnder Dang Chief Business Officer at 1Cell.Ai Inc.

M

Mark Chief Executive Officer at 23Strands

IT

Ilia Tikhomirov Chief Executive Officer at 35Pharma

AD

Alistair Draffan Chief Executive Officer at 360biolabs Pty Ltd

Outreach Guidance — research Sector

Executives like David Venables in the research sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Skylark Therapeutics.

David Venables's Position in the MessageCEO Database

• •David Venables is 1 of 1 verified executive contact we track at Skylark Therapeutics.
• •2,871 verified executive contacts in research are in the MessageCEO database.
• •10,040 verified executive contacts in England are in the database.
• •22 verified contacts work at research companies in the 40.0 employee range (same size as Skylark Therapeutics).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated July 2026.

How do I reach David Venables directly?

David Venables's verified email address is available to MessageCEO Pro subscribers. They currently serve as CEO at Skylark Therapeutics. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does David Venables work for?

David Venables is CEO at Skylark Therapeutics, a company in the research sector with 40.0 employees. The company is based in London, England.

Can I pitch or sell to David Venables?

As CEO at Skylark Therapeutics, David Venables is a key decision-maker in the research sector. MessageCEO Pro gives you verified email to reach David Venables directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is David Venables in?

David Venables works in the research industry as CEO at Skylark Therapeutics. MessageCEO provides verified contact information for executives across all major industries.

Is David Venables's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. David Venables's profile is kept up-to-date with the latest available information.

Last updated: July 31, 2026